Dr. John Restaino is a senior partner with the firm of Dalimonte Rueb Stoller, located in Carlsbad, CA.
Dr. Restaino practiced reconstructive surgery of the foot and ankle from 1980 to 1990 and has practiced at the law since 1991.
He obtained his Master of Public Health degree from the Division of Epidemiology at the Johns Hopkins Bloomberg School of Public Health in 2008.
Dr. Restaino is an (Adjunct) Associate Professor at the University of South Carolina College (USC) of Pharmacy where he is actively involved in scientific pharmacovigilance. Dr. Restaino and the USC team were amongst to see the association between the fluoroquinolone drugs and aortic disorders.
Dr. Restaino has been or is the chair, or co-chair, of the Expert & Science Committees of numerous federal MDLs dating back to the Silone Breast Implant Litigation and is currently involved in both the medical and legal evaluation of the talc/ovarian cancer litigation and the association between proton pump inhibitors and gastric cancer, in addition to the Zantac litigation. Dr. Restaino has been appointed as the chair of the epidemiology subcommittee within the Talcum Powder MDL and to the Science Committee within the Zantac MDL.
